BOULDER, Colo.–(BUSINESS WIRE)–PanTheryx announced today that CEO Mark Braman is retiring and nutrition industry veteran, Wes Parris, formerly of I-Health, Inc., will replace Braman as CEO effective immediately. PanTheryx has also announced the appointment of David Abramson to the Board of Directors who will assume the role as Executive Chairman.
Craig Cogut, Chairman of the Board, stated, “We thank Mark for his service, leadership and for positioning the company for excellent growth. We wish him well in retirement. Moving forward, we enthusiastically welcome Wes and David. We believe their experience building leading wellness and nutrition brands will be a great benefit to the Company in the future.”
Wes Parris brings over a decade of executive experience within the health and wellness industry. As the President & CEO of I-Health, Inc. (a subsidiary of DSM), Wes led all operations including sales, marketing, research and development, and business development. During his almost 13 years with the company he established and grew a category-leading consumer brand portfolio. These brands include Culturelle (the #1 global probiotic brand), AZO (the #1 global OTC urinary health brand), Estroven (the #1 global menopause symptom relief brand) and Ovega-3 (a leading brand in the vegetarian omega 3 category). Wes is an alumnus of the University of North Carolina at Chapel Hill and the Harvard Business School (General Management Program).
Mr. Parris stated, “I am thrilled to join PanTheryx at such a promising time in its growth and evolution. As nature’s perfect first food, colostrum has tremendous health benefits for all age groups. I believe PanTheryx employs the most stringent quality control measures to deliver best-in-class proprietary colostrum ingredients. These ingredients will be the backbone for new customer relationships and research and development efforts designed to bring transformative health and wellness solutions to consumers worldwide.”
David Abramson has built a career in advising emerging growth, middle-market companies, and large multi-national companies primarily in the health and wellness and nutritional markets. Formerly, David was President of Martek Biosciences Corporation (Nasdaq: MATK) where he played a key role in transitioning Martek’s business from a research and development company to a fully-integrated commercial organization. He personally developed and implemented the branding strategy for Life’s DHA, one of the most successful branded food ingredients, while leading efforts to include Life’s DHA in over 500 commercial products.
The addition of Wes Parris and David Abramson follows a pivotal year in which the Company announced that PanTheryx bovine colostrum was recognized as GRAS, key colostrum supply arrangements were inked with new customers, and a $50 million financing was secured to accelerate development of new products.
PanTheryx is a biotechnology company committed to realizing the potential of bovine colostrum-based therapies to address a wide range of health conditions. The company commercializes first-in-class therapeutics, with products developed from its patented technology platform spanning the range of nutritional interventions to biologics.
PanTheryx is the premier supplier of bovine colostrum globally, which has extensive applications in health and wellness, including GI health. Founded in 2007, PanTheryx is headquartered in Boulder, Colorado and has production facilities in Phoenix, AZ and Ripon, CA. Its first branded colostrum product, DiaResQ® is available in over 30,000 pharmacies and retail stores in the U.S.